Despite a series of major initiatives in the first quarter of this year, Injective has seen its price continue to trend downward, now sitting in the deep oversold zone. While this signals the possibility of a short-term bounce, the overall…
Despite a series of major initiatives in the first quarter of this year, Injective has seen its price continue to trend downward, now sitting in the deep oversold zone. While this signals the possibility of a short-term bounce, the overall…